Does the media prefer IOVA or PROK?

In the previous week, Iovance Biotherapeutics and Iovance Biotherapeutics both had 17 articles in the media. Iovance Biotherapeutics' average media sentiment score of 0.75 beat ProKidney's score of -0.22 indicating that Iovance Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Iovance Biotherapeutics 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive ProKidney 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to TYRA or PROK?

In the previous week, ProKidney had 14 more articles in the media than Tyra Biosciences. MarketBeat recorded 17 mentions for ProKidney and 3 mentions for Tyra Biosciences. ProKidney's average media sentiment score of -0.22 beat Tyra Biosciences' score of -0.38 indicating that ProKidney is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tyra Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ProKidney 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer MESO or PROK?

ProKidney has a consensus target price of $12.00, suggesting a potential upside of 754.09%. Given ProKidney's stronger consensus rating and higher possible upside, analysts plainly believe ProKidney is more favorable than Mesoblast. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mesoblast 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ProKidney 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has stronger valuation and earnings, MESO or PROK?

ProKidney has lower revenue, but higher earnings than Mesoblast. Mesoblast is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mesoblast $17.20M 124.52 -$102.14M -$0.28 N/A ProKidney $890K 476.85 -$68.99M -$0.55 N/A

Is MESO or PROK more profitable?

Mesoblast has a net margin of 0.00% compared to ProKidney's net margin of -10,288.39%. Company Net Margins Return on Equity Return on Assets Mesoblast N/A N/A N/A ProKidney -10,288.39% N/A -25.76%

Does the media prefer MESO or PROK?

In the previous week, ProKidney had 14 more articles in the media than Mesoblast. MarketBeat recorded 17 mentions for ProKidney and 3 mentions for Mesoblast. Mesoblast's average media sentiment score of 0.86 beat ProKidney's score of -0.22 indicating that Mesoblast is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mesoblast 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive ProKidney 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to AUPH or PROK?

In the previous week, ProKidney had 11 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 17 mentions for ProKidney and 6 mentions for Aurinia Pharmaceuticals. Aurinia Pharmaceuticals' average media sentiment score of 0.48 beat ProKidney's score of -0.22 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aurinia Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral ProKidney 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to AGIO or PROK?

In the previous week, ProKidney had 9 more articles in the media than Agios Pharmaceuticals. MarketBeat recorded 17 mentions for ProKidney and 8 mentions for Agios Pharmaceuticals. Agios Pharmaceuticals' average media sentiment score of 0.90 beat ProKidney's score of -0.22 indicating that Agios Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agios Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ProKidney 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

ProKidney (PROK) Competitors

$1.40 -0.08 (-5.07%)

Closing price 08/13/2026 04:00 PM Eastern

Extended Trading

$1.44 +0.03 (+2.14%)

As of 08:45 AM Eastern

Compare

PROK vs. IOVA, TYRA, MESO, AUPH, and AGIO

Should you buy ProKidney stock or one of its competitors? ProKidney's main competitors and comparable companies include Iovance Biotherapeutics (IOVA), Tyra Biosciences (TYRA), Mesoblast (MESO), Aurinia Pharmaceuticals (AUPH), and Agios Pharmaceuticals (AGIO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does ProKidney compare to Iovance Biotherapeutics?

Iovance Biotherapeutics (NASDAQ:IOVA) and ProKidney (NASDAQ:PROK) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and risk.

In the previous week, Iovance Biotherapeutics and Iovance Biotherapeutics both had 17 articles in the media. Iovance Biotherapeutics' average media sentiment score of 0.75 beat ProKidney's score of -0.22 indicating that Iovance Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Iovance Biotherapeutics	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
ProKidney	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Iovance Biotherapeutics has a beta of 0.71, meaning that its stock price is 29% less volatile than the broader market. Comparatively, ProKidney has a beta of 1.66, meaning that its stock price is 66% more volatile than the broader market.

ProKidney has lower revenue, but higher earnings than Iovance Biotherapeutics. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iovance Biotherapeutics	$324.97M	9.09	-$390.98M	-$0.73	N/A
ProKidney	$890K	476.85	-$68.99M	-$0.55	N/A

Iovance Biotherapeutics has a net margin of -89.11% compared to ProKidney's net margin of -10,288.39%. ProKidney's return on equity of 0.00% beat Iovance Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iovance Biotherapeutics	-89.11%	-40.92%	-31.66%
ProKidney	-10,288.39%	N/A	-25.76%

Iovance Biotherapeutics presently has a consensus target price of $8.00, suggesting a potential upside of 22.70%. ProKidney has a consensus target price of $12.00, suggesting a potential upside of 754.09%. Given ProKidney's stronger consensus rating and higher possible upside, analysts plainly believe ProKidney is more favorable than Iovance Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iovance Biotherapeutics	2 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
ProKidney	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

77.0% of Iovance Biotherapeutics shares are held by institutional investors. Comparatively, 51.6% of ProKidney shares are held by institutional investors. 7.8% of Iovance Biotherapeutics shares are held by company insiders. Comparatively, 39.8% of ProKidney shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

ProKidney beats Iovance Biotherapeutics on 11 of the 16 factors compared between the two stocks.

How does ProKidney compare to Tyra Biosciences?

Tyra Biosciences (NASDAQ:TYRA) and ProKidney (NASDAQ:PROK) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations, media sentiment and institutional ownership.

ProKidney has higher revenue and earnings than Tyra Biosciences. Tyra Biosciences is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.40	N/A
ProKidney	$890K	476.85	-$68.99M	-$0.55	N/A

Tyra Biosciences has a beta of 0.77, indicating that its stock price is 23% less volatile than the broader market. Comparatively, ProKidney has a beta of 1.66, indicating that its stock price is 66% more volatile than the broader market.

Tyra Biosciences presently has a consensus target price of $46.90, indicating a potential upside of 87.45%. ProKidney has a consensus target price of $12.00, indicating a potential upside of 754.09%. Given ProKidney's higher possible upside, analysts clearly believe ProKidney is more favorable than Tyra Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tyra Biosciences	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87
ProKidney	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Tyra Biosciences has a net margin of 0.00% compared to ProKidney's net margin of -10,288.39%. ProKidney's return on equity of 0.00% beat Tyra Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tyra Biosciences	N/A	-46.39%	-43.07%
ProKidney	-10,288.39%	N/A	-25.76%

84.1% of Tyra Biosciences shares are held by institutional investors. Comparatively, 51.6% of ProKidney shares are held by institutional investors. 12.5% of Tyra Biosciences shares are held by insiders. Comparatively, 39.8% of ProKidney shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, ProKidney had 14 more articles in the media than Tyra Biosciences. MarketBeat recorded 17 mentions for ProKidney and 3 mentions for Tyra Biosciences. ProKidney's average media sentiment score of -0.22 beat Tyra Biosciences' score of -0.38 indicating that ProKidney is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tyra Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ProKidney	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

ProKidney beats Tyra Biosciences on 11 of the 15 factors compared between the two stocks.

How does ProKidney compare to Mesoblast?

Mesoblast (NASDAQ:MESO) and ProKidney (NASDAQ:PROK) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation, media sentiment and analyst recommendations.

Mesoblast has a net margin of 0.00% compared to ProKidney's net margin of -10,288.39%.

Company	Net Margins	Return on Equity	Return on Assets
Mesoblast	N/A	N/A	N/A
ProKidney	-10,288.39%	N/A	-25.76%

ProKidney has lower revenue, but higher earnings than Mesoblast. Mesoblast is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mesoblast	$17.20M	124.52	-$102.14M	-$0.28	N/A
ProKidney	$890K	476.85	-$68.99M	-$0.55	N/A

1.4% of Mesoblast shares are owned by institutional investors. Comparatively, 51.6% of ProKidney shares are owned by institutional investors. 18.8% of Mesoblast shares are owned by insiders. Comparatively, 39.8% of ProKidney shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, ProKidney had 14 more articles in the media than Mesoblast. MarketBeat recorded 17 mentions for ProKidney and 3 mentions for Mesoblast. Mesoblast's average media sentiment score of 0.86 beat ProKidney's score of -0.22 indicating that Mesoblast is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mesoblast	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
ProKidney	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Mesoblast has a beta of 2.08, indicating that its stock price is 108% more volatile than the broader market. Comparatively, ProKidney has a beta of 1.66, indicating that its stock price is 66% more volatile than the broader market.

ProKidney has a consensus target price of $12.00, suggesting a potential upside of 754.09%. Given ProKidney's stronger consensus rating and higher possible upside, analysts plainly believe ProKidney is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mesoblast	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ProKidney	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

ProKidney beats Mesoblast on 10 of the 16 factors compared between the two stocks.

How does ProKidney compare to Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals (NASDAQ:AUPH) and ProKidney (NASDAQ:PROK) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.

Aurinia Pharmaceuticals currently has a consensus price target of $17.67, suggesting a potential upside of 16.38%. ProKidney has a consensus price target of $12.00, suggesting a potential upside of 754.09%. Given ProKidney's stronger consensus rating and higher possible upside, analysts plainly believe ProKidney is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurinia Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17
ProKidney	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, ProKidney had 11 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 17 mentions for ProKidney and 6 mentions for Aurinia Pharmaceuticals. Aurinia Pharmaceuticals' average media sentiment score of 0.48 beat ProKidney's score of -0.22 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aurinia Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
ProKidney	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aurinia Pharmaceuticals has a beta of 1.42, suggesting that its stock price is 42% more volatile than the broader market. Comparatively, ProKidney has a beta of 1.66, suggesting that its stock price is 66% more volatile than the broader market.

Aurinia Pharmaceuticals has higher revenue and earnings than ProKidney. ProKidney is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurinia Pharmaceuticals	$311.51M	6.48	$287.20M	$2.29	6.63
ProKidney	$890K	476.85	-$68.99M	-$0.55	N/A

Aurinia Pharmaceuticals has a net margin of 100.84% compared to ProKidney's net margin of -10,288.39%. Aurinia Pharmaceuticals' return on equity of 26.11% beat ProKidney's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurinia Pharmaceuticals	100.84%	26.11%	19.89%
ProKidney	-10,288.39%	N/A	-25.76%

36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. Comparatively, 51.6% of ProKidney shares are owned by institutional investors. 10.4% of Aurinia Pharmaceuticals shares are owned by company insiders. Comparatively, 39.8% of ProKidney shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Aurinia Pharmaceuticals and ProKidney tied by winning 8 of the 16 factors compared between the two stocks.

How does ProKidney compare to Agios Pharmaceuticals?

Agios Pharmaceuticals (NASDAQ:AGIO) and ProKidney (NASDAQ:PROK) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.

ProKidney has lower revenue, but higher earnings than Agios Pharmaceuticals. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agios Pharmaceuticals	$54.03M	36.98	-$412.78M	-$7.01	N/A
ProKidney	$890K	476.85	-$68.99M	-$0.55	N/A

Agios Pharmaceuticals has a net margin of -418.24% compared to ProKidney's net margin of -10,288.39%. ProKidney's return on equity of 0.00% beat Agios Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agios Pharmaceuticals	-418.24%	-35.67%	-33.06%
ProKidney	-10,288.39%	N/A	-25.76%

Agios Pharmaceuticals has a beta of 0.58, meaning that its stock price is 42% less volatile than the broader market. Comparatively, ProKidney has a beta of 1.66, meaning that its stock price is 66% more volatile than the broader market.

Agios Pharmaceuticals currently has a consensus price target of $41.25, indicating a potential upside of 23.24%. ProKidney has a consensus price target of $12.00, indicating a potential upside of 754.09%. Given ProKidney's stronger consensus rating and higher possible upside, analysts clearly believe ProKidney is more favorable than Agios Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.40
ProKidney	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

51.6% of ProKidney shares are owned by institutional investors. 5.4% of Agios Pharmaceuticals shares are owned by company insiders. Comparatively, 39.8% of ProKidney shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, ProKidney had 9 more articles in the media than Agios Pharmaceuticals. MarketBeat recorded 17 mentions for ProKidney and 8 mentions for Agios Pharmaceuticals. Agios Pharmaceuticals' average media sentiment score of 0.90 beat ProKidney's score of -0.22 indicating that Agios Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agios Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ProKidney	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

ProKidney beats Agios Pharmaceuticals on 13 of the 17 factors compared between the two stocks.

Get ProKidney News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PROK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PROK vs. The Competition

Export

Metric	ProKidney	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$447.05M	$3.75B	$7.07B	$13.00B
Dividend Yield	N/A	3.76%	2.58%	10.72%
P/E Ratio	-2.55	10.24	269.63	25.21
Price / Sales	476.85	1,291.38	596.72	99.91
Price / Cash	N/A	103.01	70.53	50.75
Price / Book	-0.42	17.68	13.11	6.24
Net Income	-$68.99M	-$13.30M	$3.45B	$347.70M
7 Day Performance	-14.33%	0.65%	0.78%	0.87%
1 Month Performance	-9.35%	0.50%	1.45%	0.90%
1 Year Performance	-41.94%	54.56%	67.07%	20.13%

ProKidney Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PROK ProKidney	1.8889 of 5 stars	$1.41 -5.1%	$12.00 +754.1%	-40.7%	$447.05M	$890K	N/A	3	Trending News Earnings Report Analyst Revision
IOVA Iovance Biotherapeutics	2.6125 of 5 stars	$4.34 -0.5%	$8.43 +94.2%	+165.6%	$1.95B	$263.50M	N/A	500
TYRA Tyra Biosciences	2.619 of 5 stars	$25.71 -21.0%	$46.90 +82.4%	+132.7%	$1.93B	N/A	N/A	20	High Trading Volume
MESO Mesoblast	0.2685 of 5 stars	$14.97 +1.1%	N/A	+8.6%	$1.92B	$17.20M	N/A	80
AUPH Aurinia Pharmaceuticals	3.7173 of 5 stars	$15.19 +1.7%	$17.33 +14.1%	+26.4%	$1.92B	$283.05M	7.00	300	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PROK) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ProKidney (PROK) Competitors

PROK vs. IOVA, TYRA, MESO, AUPH, and AGIO

How does ProKidney compare to Iovance Biotherapeutics?

Summary

How does ProKidney compare to Tyra Biosciences?

Summary

How does ProKidney compare to Mesoblast?

Summary

How does ProKidney compare to Aurinia Pharmaceuticals?

Summary

How does ProKidney compare to Agios Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PROK vs. The Competition

ProKidney Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ProKidney (PROK) Competitors

PROK vs. IOVA, TYRA, MESO, AUPH, and AGIO

How does ProKidney compare to Iovance Biotherapeutics?

Does the media prefer IOVA or PROK?

Which has more volatility & risk, IOVA or PROK?

Which has higher earnings and valuation, IOVA or PROK?

Is IOVA or PROK more profitable?

Do analysts rate IOVA or PROK?

Do institutionals & insiders hold more shares of IOVA or PROK?

Summary

How does ProKidney compare to Tyra Biosciences?

Which has higher earnings & valuation, TYRA or PROK?

Which has more volatility & risk, TYRA or PROK?

Do analysts prefer TYRA or PROK?

Is TYRA or PROK more profitable?

Do institutionals and insiders believe in TYRA or PROK?

Does the media refer more to TYRA or PROK?

Summary

How does ProKidney compare to Mesoblast?

Is MESO or PROK more profitable?

Which has stronger valuation and earnings, MESO or PROK?

Do insiders & institutionals hold more shares of MESO or PROK?

Does the media prefer MESO or PROK?

Which has more volatility and risk, MESO or PROK?

Do analysts prefer MESO or PROK?

Summary

How does ProKidney compare to Aurinia Pharmaceuticals?

Do analysts recommend AUPH or PROK?

Does the media refer more to AUPH or PROK?

Which has more volatility and risk, AUPH or PROK?

Which has stronger earnings and valuation, AUPH or PROK?

Is AUPH or PROK more profitable?

Do institutionals and insiders have more ownership in AUPH or PROK?

Summary

How does ProKidney compare to Agios Pharmaceuticals?

Which has better earnings & valuation, AGIO or PROK?

Is AGIO or PROK more profitable?

Which has more volatility & risk, AGIO or PROK?

Do analysts prefer AGIO or PROK?

Do insiders & institutionals have more ownership in AGIO or PROK?

Does the media refer more to AGIO or PROK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PROK vs. The Competition

ProKidney Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools